Cargando…
d-Dimer elevation and adverse outcomes
d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevate...
Autores principales: | Halaby, Rim, Popma, Christopher J., Cohen, Ander, Chi, Gerald, Zacarkim, Marcelo Rodrigues, Romero, Gonzalo, Goldhaber, Samuel Z., Hull, Russell, Hernandez, Adrian, Mentz, Robert, Harrington, Robert, Lip, Gregory, Peacock, Frank, Welker, James, Martin-Loeches, Ignacio, Daaboul, Yazan, Korjian, Serge, Gibson, C. Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300425/ https://www.ncbi.nlm.nih.gov/pubmed/25006010 http://dx.doi.org/10.1007/s11239-014-1101-6 |
Ejemplares similares
-
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial
por: Gibson, C. Michael, et al.
Publicado: (2018) -
The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification
por: Gibson, C. Michael, et al.
Publicado: (2017) -
Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
por: Gibson, C. Michael, et al.
Publicado: (2017) -
Pheochromocytoma Presenting as Partial HELLP Syndrome
por: Daaboul, Yazan, et al.
Publicado: (2015) -
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
por: Yee, Megan K., et al.
Publicado: (2019)